HOME >> BIOLOGY >> NEWS
Electric fish in Africa could be example of evolution in action

d no detectable variation in the genetic markers we studied," Arnegard said.

Because all of the 20 or so species of mormyrid have distinct electric signals, Arnegard believes the different impulses of the fish he studies might be their first step in diverging into different species.

"This might be a snapshot of evolution," Arnegard said.

Understanding how animals become different species, a process known as speciation, is a major concern in understanding evolution. Arnegard's fish may allow researchers to test if a specific type of speciation is possible.

One common type of speciation is geographically dependent. Animals diverge into separate species because they become physically isolated from each other. Eventually, genes within each group mutate so that the groups can no longer be considered to be of the same species.

Another type of speciation, which many scientists have found harder to imagine, involves animals that live in the same geographic location but, for some reason, begin to mate selectively and form distinct groups and, ultimately, separate species. This so-called sympatric speciation is more controversial because there have been few accepted examples of it to date.

"Many scientists claim it's not feasible," Arnegard said. "But it could be a detection problem because speciation occurs over so many generations." These Gabon fishes' impulses, however, can change very quickly in comparison. So Arnegard suspects that the different shapes of the electric impulses from these mormyrids might be a first step in sympatric speciation.

One the other hand, the fish could be a single species. "This could be just a polymorphism, like eye color in humans, that violates the fishes' general evolutionary pattern but doesn't give rise to separate species," said Arnegard, who will return to Gabon in June to conduct further tests, funded by the National Geographic Society.


'"/>

Contact: Susan S. Lang
ssl4@cornell.edu
607-255-3613
Cornell University News Service
1-Jun-2006


Page: 1 2

Related biology news :

1. Electric fish conduct electric duets in aquatic courtship
2. Electric fish shed light on ways the brain directs movement
3. Electrical activity alters language used by nerve cells
4. Electrical stimulation boosts stroke recovery
5. Electrical engineer works on personalizing medical treatment
6. Link between sunspots, rain helps predict disease in east Africa
7. Space-borne sensors help Africa tackle water shortage problems
8. New research proves single origin of humans in Africa
9. Clues to future evolution of HIV come from African green monkeys
10. First all-African produced genetically engineered maize is resistant to maize streak virus
11. Biocontrol of invasive water hyacinth contributes to socioeconomic and health improvements in Africa

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Electric fish Africa could example evolution action

(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: